Blueprint Medicines Corp.

As of October 28, 2021, Blueprint Medicines Corp. is considered overvalued with a risky valuation grade, indicated by high Price to Book and EV to Capital Employed ratios, a negative EV to EBITDA compared to peers, and despite a strong year-to-date return, its current price level is not justified.

As of October 28, 2021, Blueprint Medicines Corp. is considered risky and overvalued due to its negative P/E ratio, high Price to Book Value of 24.13, and unfavorable EV to EBITDA of -52.59, despite a strong year-to-date stock performance of 47.21% compared to the S&P 500's 2.44%.

As of June 4, 2025, the market trend is bullish, supported by strong indicators like a bullish MACD and moving averages, although the weekly RSI shows some short-term weakness.

As of March 2022, the management team of Blueprint Medicines Corp. includes CEO Jeffrey Albers and Independent Chairman Daniel Lynch, along with several independent directors: Alexis Borisy, Lonnel Coats, George Demetri, Mark Goldberg, and Nicholas Lydon. The team consists of both executive leadership and independent directors.

Blueprint Medicines Corporation is a biopharmaceutical company focused on treating genomically defined diseases caused by abnormal kinase activation. As of March 2025, it reported net sales of $149 million and has a market capitalization of approximately $8.29 billion.

As of Jun 18, Blueprint Medicines Corp. has a market capitalization of $8.29 billion, with net sales of $562.12 million and a net profit of -$155.73 million over the latest four quarters. Shareholder's funds are $298.67 million, and total assets amount to $1.18 billion.